What does Crescent Biopharma, Inc. do?
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic…
What is Crescent Biopharma, Inc.'s P/E and P/B ratio?
Crescent Biopharma, Inc. has a P/E ratio of -1.7 and a P/B ratio of 2.99.
What is Crescent Biopharma, Inc.'s debt-to-equity ratio?
Crescent Biopharma, Inc. has a debt-to-equity ratio of 0.01.
How much does Crescent Biopharma, Inc. owe compared with what it owns?
Crescent Biopharma, Inc. owes $0.11 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Crescent Biopharma, Inc.'s Positivity rank?
Crescent Biopharma, Inc. is ranked #3,906 of 6,774 companies globally and #1,816 of 4,000 in United States on PositoAI, with a Positivity Score of 20,108.
Does Crescent Biopharma, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Crescent Biopharma, Inc..
Where can I read the latest news about Crescent Biopharma, Inc.?
Recent headlines about Crescent Biopharma, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Crescent Biopharma, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Crescent Biopharma, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.